Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Geranylgeranyltransferase type I (GGTase-I) is an essential eukaryotic enzyme that catalyzes the posttranslational modification of proteins by transferring a geranylgeranyl group to the cysteine residue within a C-terminal CaaX motif of target proteins. This facilitates membrane association and proper function of numerous signaling proteins, especially those involved in cell regulation and oncogenesis. GGTase-I is a heterodimer composed of two subunits: alpha (FNTA gene) and beta (PGGT1B gene). It modifies more than 100 different proteins, including many small GTP-binding regulatory proteins such as members of the Rho family and some Ras-related proteins. Due to its role in cancer progression, inhibition of GGTase-I has been explored as an anti-cancer strategy.
Inhibition of geranylgeranylation of target proteins, particularly Rho family GTPases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Geranylgeranyltransferase type I (GGTase-I).